Precision BioSciences announced that the U.S. Food and Drug Administration has granted a Study May Proceed notification for its PBGENE‑DMD gene‑editing therapy, allowing the company to initiate institutional review board activities and activate clinical trial sites for the FUNCTION‑DMD Phase 1/2 study.
PBGENE‑DMD uses Precision’s ARCUS platform to excise the disease‑causing exon from the dystrophin gene, restoring a near full‑length protein that can improve muscle function. The therapy targets ambulatory Duchenne muscular dystrophy patients with mutations between exons 45 and 55, a genetic subset that represents roughly 60 % of the DMD population.
The FDA notification is a critical de‑risking event that moves PBGENE‑DMD from pre‑clinical development into the first human trials. It also signals that the company’s proprietary gene‑editing technology is progressing through the regulatory pipeline, potentially unlocking commercial opportunities in a large, underserved market where current treatments are limited.
CEO Michael Amoroso said the approval “represents yet another regulatory achievement for Precision BioSciences as we advance our second wholly‑owned program toward the clinic.” He added that the milestone demonstrates the viability of the ARCUS platform and the company’s commitment to delivering transformative therapies for rare diseases.
Precision plans to activate the first U.S. clinical site in the first half of 2026 and expects initial data from multiple patients by the end of the year. The company’s broader pipeline includes other ARCUS‑based candidates, and its financial position provides the cash runway needed to support the upcoming trial while maintaining investment in future programs.
The announcement underscores the company’s strategic focus on gene‑editing solutions for rare diseases and highlights the potential for PBGENE‑DMD to address a substantial portion of the DMD patient population, positioning Precision BioSciences as a key player in the evolving gene‑therapy landscape.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.